Lung Fluid Biomarkers for Acute Respiratory Distress Syndrome

A Systematic Review and Meta-analysis

Yishan Wang; Huijuan Wang; Chunfang Zhang; Chao Zhang; Huqin Yang; Ruiyue Gao; Zhaohui Tong

Disclosures

Crit Care. 2019;23(43) 

In This Article

Results

Literature Search

The total literature search yielded 1156 articles from the databases as follows: PubMed, 340 articles; Web of Science, 522 articles; Embase, 279 articles; Cochrane Library, 12 articles; and 3 articles from the reference lists of included studies. By reviewing the titles and abstracts, studies were mainly excluded due to the following: in vitro/animal studies (n = 434), duplication (n = 423), not an original research (reviews, editorials, or case reports, n = 90), and biomarkers not related with occurrence or mortality of ARDS (n = 30). After the initial screening, 95 articles remained for full-text review. Of these, 25 articles only reported on a specific biomarker, 16 articles contained insufficient data, and 4 articles had no full-text copy available, despite attempts to contact the authors. The remaining 49 articles were used for the meta-analysis[12–60] (Figure 1).

Figure 1.

Flowchart of study selection. ARDS, acute respiratory distress syndrome; ALI, acute lung injury; vs, versus

Study Characteristics and Quality Assessment

Demographic variables of the included studies are summarized in (Table 1). A total of 49 articles involving 2189 patients were included in this meta-analysis. ARDS/ALI was diagnosed according to the AECC criteria in 71% of the studies. Other criteria, such as edema fluid/plasma protein ratio,[61] lung injury score,[62] Fowler criteria,[63] and clinical criteria, were used along with the AECC criteria. The mean age ranged from 37 to 70 years, mortality rate ranged from 15 to 77%, and lung fluid was collected between 30 min of intubation and 72 h of ARDS diagnosis. As for sample retrieval location, the right middle lobe and lingular lobe were the most common. Other locations were based on abnormal areas identified on chest radiographs, and a blind sampling of BALF was performed in two studies. In regard to sample type, 69% of the studies measured biomarkers in BALF with a certain volume of irrigation solution. Ten articles used pulmonary edema fluid, and four articles measured a biomarker in epithelial lining fluid. Only three articles provided the recovery rate of the irrigation solution; therefore, we could only assume a stable recovery rate between subgroups for this study.

The ARDS etiologies are summarized in Additional file 3. The most common cause of ARDS was sepsis (30.87%), followed by pneumonia (23.70%), trauma (10.94%), aspiration (8.53%), transfusion (4.23%), and major surgery (3.47%). Other etiologies included vasculitis, retroperitoneal hematoma-DIC, drug overdose, reperfusion injury, and diabetic ketoacidosis.

The quality assessment is displayed in Additional file 4, including the risk of bias and applicability of studies to the review question.

Biomarkers Associated With ARDS Diagnosis

We performed a meta-analysis on 22 biomarkers in lung fluid associated with the diagnosis of ARDS in the at-risk population (Table 2); Figure 2 shows the forest plots for biomarkers available in at least 3 studies. Pooled RoM values for total phospholipases A2 activity (total PLA2 activity) (17.995 [11.381, 28.454]), total protein (9.299 [7.575, 11.414]), albumin (6.544 [4.908, 8.725]), plasminogen activator inhibitor-1 (PAI-1) (5.525 [3.876, 7.877]), soluble receptor for advanced glycation end products (sRAGE) (4.901 [3.603, 7.673]), platelet activating factor-acetyl choline (PAF-AcH) (4.783 [3.495, 6.545]), soluble tumor necrosis factor-α receptors II (STNF-RII) (3.253 [1.765, 5.993]), hepatic growth factor (HGF) (3.199 [1.668, 6.135]), and interleukin-8 (IL-8) (3.008 [2.322, 3.896]) were the highest. The overall effect size ranged from 0.548 to 17.995, among biomarkers with significant RoM between subgroups, and decreased Club cell protein (CC16) (0.553 [0.369, 0.827]) and matrix metalloproteinases-9 (MMP-9) (0.548 [0.336, 0.893]) levels in lung fluid indicated a higher possibility of ARDS diagnosis in the at-risk population. However, a pervasive heterogeneity was displayed.

Figure 2.

Forest plot for acute respiratory distress syndrome (ARDS) diagnosis. RoM, ratio of means; CI, confident interval; IL-6, interleukin-6; IL-8, interleukin-8; PAF-ACH, platelet activating factor-acetyl choline; PCPIII, procollagen peptide III

We performed an influence analysis to examine the sensitivity of the results. Influence analysis showed that the heterogeneity was possibly caused by the limited number of studies. By removing the studies with extreme RoM, we observed a robust effect on the biomarkers. The outcome of the influence analysis is displayed in Additional file 5.

Subgroup analysis was performed for biomarkers IL-8, total protein, albumin, sRAGE, PAF-AcH, and IL-6. Since most of the included studies were case-control studies, we excluded studies with other design types. Heterogeneity for total protein, albumin, and IL-6 was partly explained. However, heterogeneity for IL-8 was not clarified. Only one article was case-control study; therefore, the source of heterogeneity was not determined for PAF-AcH because of a limited number of study. We also excluded studies with ARDS that was not diagnosed using AECC criteria, which significantly reduced the heterogeneity for IL-6, but not for albumin. In addition, we assumed sample type may be a variable between studies because biomarker measurement in BALF was influenced by recovery rate and dilution. IL-8 remained significantly increased when BALF studies were excluded. As only one article measured biomarkers in lung fluid other than BALF, it was not evaluated. Results of the subgroup analysis are presented in Additional file 6.

Biomarkers Associated With ARDS Mortality

We performed a meta-analysis on 11 biomarkers in lung fluid associated with ARDS mortality (Table 3); Figure 3 shows the forest plots for biomarkers associated with ARDS mortality. Interleukin-1β (IL-1β) (4.617 [4.331, 4.921]), IL-6 (3.882 [3.270, 4.608]), IL-8 (3.679 [3.414, 3.964]), and Kerbs von Lungren-6 (KL-6) (3.178 [2.931, 3.446]) ranked the highest in biomarkers associated with ARDS mortality. The overall effect size ranged from 0.406 to 4.617. Among the biomarkers with a significant difference between survivors and non-survivors, decreased levels of interleukin-2 (IL-2) (0.828 [0.715, 0.959]) and CC16 (0.406 [0.362, 0.405]) were associated with a high mortality rate. Heterogeneity was displayed for many of the biomarkers, and influence analysis indicated that the heterogeneities were not likely caused by extreme RoM values. Due to the small number of studies, subgroup analysis based on design type or sample type could not be performed. Subgroup analysis for tumor necrosis factor-α (TNF-α) was performed when excluding patients with ARDS not diagnosed using AECC criteria. Results of the subgroup analysis are presented in Additional file 7.

Figure 3.

Forest plot for acute respiratory distress syndrome (ARDS) mortality. RoM, ratio of means; CI, confident interval; IL-6, interleukin-6; IL-8, interleukin-8

Publication Bias

Among the biomarkers associated with ARDS, Egger's regression test demonstrated a p value of less than 0.10 for IL-6; furthermore, when we adjusted for possible publication bias by Duval and Tweedie's trim and fill, the RoM remained significant for IL-6. Among the biomarkers associated with mortality, no publication bias was noted. The results of the publication bias analysis are presented in Additional file 8.

Comments

3090D553-9492-4563-8681-AD288FA52ACE

processing....